IGF1 and neoplasm: Of the results that showed statistically significant changes, the addition of IGF-1 to tumour cell lines increased the resistance to chemotherapy: WiDr 5-FU in normal glucose at 24 h (P<0.001) and 4 h (P<0.001); WiDr oxaliplatin in normal glucose at 24 h (P<0.001) and 4 h (P<0.001); SW620 5-FU in normal glucose at 0 h (P=0.007); and SW620 irinotecan in high glucose at 4 h (P=0.015).